BIOTRONIK

Trusted

http://www.biotronik.com/

Last activity: 14.08.2026

Active

Categories: CardiologyHealthcareInnovationMedicalDeviceTechnology

At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries. Quality in every detail. From the very start, BIOTRONIK dedicated itself to driving progress and innovation and delivering exceptional quality. We have earned the trust of medical professionals and patients by combining the renowned art of German engineering with technical excellence and uncompromising quality standards. This dedication is evident in everything we do. High achievers are welcome. Medical engineering is an industry of the future. In a field marked by rapid developments and short innovation cycles, the best guarantees for sustainable success are committed, creative, team-oriented specialists, and outstanding leadership. If you are passionate about computer science, engineering or the natural sciences and enjoy developing new ideas, you´ve found the right place. Are you interested? Take a look at our website www.biotronik.com/careers

Twitter Facebook LinkedIn Youtube

Followers

4.6K

Followers

153.67K

Website visits

103.5K /mo.

Mentions

Overview

Location

Germany

Employees

5001-10000

Founded date

1963

Mentions in press and media 29

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Jul 10, 2026	Global Pulsed Field Ablation Market and Forecast to 2032	The global pulsed field ablation market was valued at USD 2 billion in 2025 and is projected to reach USD 8.9 billion by 2032, expanding at a CAGR of 23.7% during the forecast period. Pulsed field ablation (PFA) is an advanced non-thermal c...
May 19, 2026	BIOTRONIK, Charité, and German Heart Center Foundation Announce Partnership to Advance Digital Cardiology	Strategic Initiative Strengthens Berlin as Europe's Hub of Digital Cardiology BERLIN, May 19, 2026 /PRNewswire/ -- BIOTRONIK, die Charité – Universitätsmedizin Berlin, and the German Heart Center Foundation today announced a research and in...
Mar 24, 2026	BIOTRONIK Leaps Forward with Next‑Generation Leadless Pacing	International BIO-LivIQ Study Will Generate Evidence for Global LivIQ Leadless Pacemaker Approvals Far-Field Sensing and AV-Synchronous Pacing Performance Will be Validated by Real World Clinical Data BERLIN, March 24, 2026 /PRNewswire/ -- ...
Sep 12, 2024	Berlin Heals Strengthens Executive Leadership Team	Berlin Heals appoints proven cardiac rhythm management and heart failure leader John Brumfield as Chief Executive Office BERLIN, Sept. 12, 2024 /PRNewswire/ -- Berlin Heals Holding AG and its subsidiaries Berlin Heals GmbH and Berlin Heals ...
Sep 11, 2024	U.S. and European Patient Monitoring Equipment Market Update: Remote Patient Monitoring, IoT, ASCs, and the Rapid EEG Market \| iData Research	VANCOUVER, BC, Sept. 11, 2024 /PRNewswire/ - iData Research, a leading global consulting and market research firm, has released new, in-depth reports on the U.S. and European patient monitoring equipment (PME) markets. The reports highlight...
May 17, 2024	Implicity Launches FDA-approved Heart Failure Prediction Algorithm, SignalHF	What You Should Know: – Implicity, a leader in remote patient monitoring and cardiac data management, has received FDA 510(k) clearance for SignalHF1, a groundbreaking new algorithm within their remote monitoring solution. – SignalHF1 algor...
Mar 13, 2024	Bio-Implants Market Analysis & Forecast for Next 5 Years \| Johnson & Johnson, Medtronic, Stryker	Bio-Implants Bio-Implants Market will witness a 10% CAGR, Top Key Players and Forecast to 2030 Stay up to date with Bio-Implants Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.”...
Mar 4, 2024	Spinal Cord Stimulation Market was valued at US$2.428 billion in 2022, witnessing significant growth	The spinal cord stimulation market was valued at US$2.428 billion in 2022. The spinal cord stimulation market was valued at US$2.428 billion in 2022.” — Knowledge Sourcing IntelligenceNOIDA, UTTAR PARDESH, INDIA, March 4, 2024 /EINPresswire...
Mar 4, 2024	Connected Medical Device Market Key Segment, Growth Opportunities forecast by 2024-2031 \| GE Healthcare, Garmin Ltd	Connected Medical Device Market share BURLINGAME, CALIFORNIA, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- Connected Medical Device Market Research focuses on the key trends prevailing in the Global Connected Medical Device Industry s...
Jul 28, 2021	BIOTRONIK's Implantable Cardiac Monitor Receives Prestigious Industry Award
Jul 28, 2021	BIOTRONIK Applauded by Frost & Sullivan for Its Disruptive Implantable Cardiac Monitoring Device, BIOMONITOR IIIm	LONDON, July 28, 2021 /PRNewswire/ -- Based on its recent analysis of the Global market for implantable cardiac monitoring devices, Frost & Sullivan recognizes BIOTRONIK with the 2021 Global Enabling Technology Leadership Award. The com...
Sep 3, 2019	ESC Congress 2019: Biotronik beats Abbott at target lesion failure	Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when it comes to target lesion failure, according to data from a clinical trial. The randomized, controlled BioSTEMI trial was the first direct ...
Jun 7, 2019	Biotronik touts success of its resorbable magnesium scaffold	Biotronik said today that new data from a European patient registry strengthen the clinical evidence for its Magmaris resorbable scaffold device, its procedure success and safety profile. The target lesion failure (TLF) rate at 12 months wa...
Jul 3, 2015	Morning Read: Aetna to buy Humana for $37B	LIFE SCIENCE BIOTRONIK is organizing a clinical trial. BIOWOMEN will focus on cardiac resynchronization therapy response in women and men to determine how women respond to the treatment. It claims to be the first study of its size to invest...
May 26, 2015	Biotronik launches home CRM monitoring, MRI-safe devices in Japan	Germany’s Biotronik is rolling out a smartphone-like device in Japan designed to transmit data to physicians from its pacemakers and defibrillators, including the Iforia line of MRI-safe implants it’s rolling out in the Land of the Rising S...
May 22, 2015	EuroPCR 2015: Edwards pauses Fortis TMVI, TAVI gains across the board	The EuroPCR conference wrapped up this week in Paris. Here’s a roundup of news from the largest overseas meeting of interventional cardiologists, dominated by Edwards Lifesciences‘ (NYSE:EW) decision to pause its Fortis transcatheter mitral...
May 12, 2015	Biotronik looks to get into the TAVI game	Biotronik today said its entry into a hot replacement heart valve market passed the safety endpoint of a 1st-in-human trial. The German medical device giant said the Biovalve trial of its transcatheter aortic valve implant established the d...
Feb 18, 2015	Studies show Biotronik pacemakers safe for MRI use	German cardiac device-maker Biotronik announced that 2 studies have confirmed its ProMRI pacemaker systems are safe to use with certain MRI procedures. The studies tracked 226 patients with ProMRI Evia/Entovis SR-T and DR-T pacemaker system...
Jan 23, 2014	Biotronik wins CE Mark for drug releasing balloon	Biotronik won European regulatory approval for its Passeo-18 Lux drug releasing balloon and the company is beginning commercial efforts in all CE Mark countries. The Passeo-18 Lux is designed to treat de novo and restenotic femoropopliteal ...
Mar 28, 2013	Biotronik lands CE Mark for MRI-safe Iforia defibrillator	Biotronik said it’s planning a mid-year launch in Europe for its Iforia MRI-safe pacemaker now that EU regulators have given the device CE Mark approval. The German medical device company said the Iforia is the world’s 1st ICD/CRT-D device ...
Jan 16, 2013	Biotronik gets FDA go-ahead for MRI-safe pacemaker trial	The FDA approved a clinical trial of Biotronik‘s Entovis MRI-safe pacemaker, granting an investigational device exemption to the German medical device company. Biotronik said it’s already enrolling subjects for the 245-patient trial, which ...
Dec 18, 2012	Biotronik’s ICD home monitoring cuts inappropriate shocks in half	Cardiovascular medical device maker Biotronik unveiled clinical results from its Effectiveness & Cost of ICD Follow-Up Schedule with Telecardiology trial, which showed that the company’s home monitoring system reduced inappropriate impl...
Nov 14, 2012	Biotronik touts IDE approval, 1st implant for Pulsar-18 stent in Bioflex-I trial	Cardiovascular medical device maker Biotronik touted FDA investigational device exemption for and 1st U.S. implantation of its Pulsar-18 self-expanding stent, the latest in the company’s line of peripheral artery stents. The FDA approval gr...
Jun 14, 2012	ENDOSENSE and BIOTRONIK Announces Market Approval of Ablation Catheter
Mar 29, 2012	Remote monitoring: Chronic illness, aging Boomers drive 16% growth	The remote patient monitoring market is expected to grow at a 16 percent compound annual rate over the next several years, driven primarily by an aging population that’s increasingly afflicted by chronic diseases. The value of the global re...
	Morning Read: Aetna to buy Humana for $37B	MedCity content will be light today in honor of the Independence Day weekend. TOP STORIES In a move that will propel it to the top of the Medicare market, Aetna will buy Humana for $37 billion. Humana’s Medicare enrollment totals 3.2 millio...
	Biotronik receives FDA device approval for ‘smaller, thinner’ one-lead implantable cardiac defibrillator	Biotronik, an Oregon-based cardiovascular medical device company, announced it received final FDA device approval for its Ilesto DX, an implantable cardiac defibrillator. Earlier this year, it received FDA device approval for family of impl...
	Remote monitoring: Chronic illness, aging Boomers drive 16% growth	The remote patient monitoring market is expected to grow at a 16 percent compound annual rate over the next several years, driven primarily by an aging population that’s increasingly afflicted by chronic diseases. The value of the global re...

Reviews 0

FAQ about BIOTRONIK

When was BIOTRONIK founded?

BIOTRONIK was founded in 1963.

What has the press written about BIOTRONIK?

Parsers VC has collected 29 articles mentioning BIOTRONIK, among them “Global Pulsed Field Ablation Market and Forecast to 2032” (Jul 10, 2026) and “BIOTRONIK, Charité, and German Heart Center Foundation Announce Partnership to Advance Digital Cardiology” (May 19, 2026).

Is BIOTRONIK still active?

Yes, BIOTRONIK is active; its latest activity on Parsers VC dates from Aug 14, 2026.